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How do We Manage Coronary Artery Disease in 
Patients with CKD and ESRD ?
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Chronic kidney disease (CKD) has been shown to be an independent risk factor 
for cardiovascular events. In addition, patients with pre-dialysis CKD appear 
to be more likely to die of heart disease than of kidney disease. CKD accelerates 
coronary artery atherosclerosis by several mechanisms, notably hypertension 
and dyslipidemia, both of which are known risk factors for coronary artery disease. 
In addition, CKD alters calcium and phosphorus homeostasis, resulting in hyper- 
calcemia and vascular calcification, including the coronary arteries. Mortality of 
patients on long-term dialysis therapy is high, with age-adjusted mortality rates 
of about 25% annually. Because the majority of deaths are caused by cardiovas- 
cular disease, routine cardiac catheterization of new dialysis patients was pro-
posed as a means of improving the identification and treatment of high-risk 
patients. However, clinicians may be uncomfortable exposing asymptomatic pa-
tients to such invasive procedures like cardiac catheterization, thus noninvasive 
cardiac risk stratification was investigated widely as a more palatable alternative 
to routine diagnostic catheterization. The effective management of coronary artery 
disease is of paramount importance in uremic patients. The applicability of diag-
nostic, preventive, and treatment modalities developed in nonuremic populations 
to patients with kidney failure cannot necessarily be extrapolated from clinical 
studies in non-kidney failure populations. Noninvasive diagnostic testing in uremic 
patients is less accurate than in nonuremic populations. Initial data suggest that 
dobutamine echocardiography may be the preferred diagnostic method. PCI with 
stenting is a less favorable alternative to CABG, however, it has a faster recovery 
time, reduced invasiveness, and no overall mortality difference in nondiabetic 
and non-CKD patients compared with CABG. CABG is associated with reduced 
repeat revascularizations, greater relief of angina, and increased long term sur- 
vival. However, CABG is associated with a higher incidence of post-operative 
risks. The treatment chosen for each patient should be an individualized decision 
based upon numerous risk factors. CKD is associated with higher rates of CAD, 
with 44% of all-cause mortality attributable to cardiac disease and about 20% 
from acute MI. Optimal treatment including aggressive lifestyle modifications 
and concomitant medical therapy should be implemented in all patients to maxi- 
mize benefits from either PCI or CABG. Future prospective randomized con-
trolled trials with newer second or third generation DES and bioabsorbable DES 
are necessary to determine if PCI may be non-inferior to CABG in the future.
Key Words: Chronic kidney disease, Coronary artery disease
Received: November 27, 2014
Accepted: December 5, 2014
Corresponding Author: Sung Kyu Ha, M.D., Ph.D. 
Division of Nephrology, Department of Internal 
Medicine, Gangnam Severance Hospital, Yonsei 
University College of Medicine, 712, Eonjuro, 
Gangnam-gu, Seoul 135-720, Korea
Tel: +82-2-2019-3313, Fax: +82-2-3463-3882
E-mail: hask1951@yuhs.ac
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License(http://creativecommons.org/licenses/by-nc/3.0/) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction
Prevalence of CKD is increasing worldwide. CKD is 
characterized by a progressive decline in glomerular filtra- 
tion rate (GFR) over several years resulting in permanent 
kidney failure requiring dialysis or transplantation. In 
2002, the National Kidney Foundation’s Kidney Disease 
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Outcomes Quality Initiative (KDOQI) introduced a con-
ceptual model for CKD. In this model, CKD was defined 
based on the presence of kidney damage or GFR (GFR 
<60ml/min/1.73m2) for ≥3 months, irrespective of cause, 
and was classified into 5 stages based on the level of GFR1). 
Then in 2011, a new classification of CKD was proposed 
by the Kidney Disease: Improving Global Outcomes
(KDIGO). They introduced a two-dimensional staging of 
the CKD according to the level of albuminuria in addition 
to the GFR level. Also, the previous CKD stage 3 was 
subdivided into two stages (G3a and G3b)2). When applied 
this new CKD classification system to the US population 
studies, about 12%(25 million) are estimated to have CKD3).
The impact of CKD on cardiovascular and all-cause 
mortality has been well-established4). A one-year mortal-
ity rate of patients with end-stage renal disease (ESRD) 
is approximately 20% in US dialysis population and the 
single most contributor to this high mortality is cardiovas- 
cular disease, which accounts for over 50% of all deaths3). 
Although patients on dialysis are at greatest risk, with 
age-specific cardiovascular mortality rates of 10-100 times 
greater than those of the general population, the increased 
risk also extends to those with milder forms of CKD5-7). 
Coronary artery disease (CAD) is the main cause of death 
in patients with CKD3), and the survival of patients with 
CKD who undergo coronary revascularization is worse 
than for other patients with CAD8). The incidence and 
severity of obstructive CAD increases as GFR declines9,10). 
In CKD, CAD has been shown to be diffuse multi-vessel 
involvement with vascular calcification11). In the US, 
about 500,000 patients are on renal replacement therapies 
(dialysis), but the number of patients with mild to mode- 
rate CKD is far greater compared to dialysis patients3).
In this article, we are going to review epidemiology, 
pathogenesis, diagnosis, and treatment of CAD in patients 
with CKD and ESRD.
Epidemiology
Patients with CKD are at substantially higher risk for 
the development of cardiovascular disease (CVD) than 
those in the general population without CKD3,12,13). CKD 
has been shown to be an independent risk factor for car-
diovascular events, and patients in the earlier stages of 
CKD are actually far more likely to die from CVD than 
to progress to ESRD14). In a large US community study 
involving over one million people, an independent, graded 
relationship was observed between estimated glomerular 
filtration rate (eGFR) and rates of death, cardiovascular 
events and hospitalization. Patients with estimated GFRs 
between 45 to 59, 30 to 44, 15 to 29 and less than 15 
mL/min per1.73 m2, had significantly higher hazard ra-
tios for any cardiovascular event compared to patients 
with GFR of greater than 60 mL/min per 1.73 m2 13). A 
similar relationship between eGFR and cardiovascular 
events was also demonstrated in the VALIANT trial of 
survivors of acute myocardial infarction complicated by 
left ventricular dysfunction. Below 81 ml/min, each 10 
unit reduction in eGFR was associated with a 10% increase 
in the relative risk of cardiovascular death and non-fatal 
events15). In patients with CKD, CAD is the well-known 
leading cause of death3) and small angiographic studies 
suggested that the incidence of CAD was more than 50% 
in unselected CKD 5D patients16,17). Among patients with 
CAD, concomitant CKD worsens the cardiovascular mor-
bidity and mortality which are associated with kidney 
function inversely and independently, particularly at esti-
mated GFR <15 ml/min per 1.73 m2 15,18,19). CKD is also 
an independent predictor of mortality in acute coronary 
syndromes (ACS) without ST segment elevation. An in-
crease in mortality and in re-infarction was evident in 
an analysis of almost 40,000 patients recorded in the data- 
bases of four acute coronary syndrome trials. They showed 
that a significant proportion of patients who present with 
ACS have abnormal renal function. Compared with patients 
with normal renal function, those with abnormal renal 
function also have more adverse baseline clinical charac- 
teristics. Most importantly, abnormal renal function is 
an independent predictor of adverse outcomes18). For di-
alysis patients, myocardial infarction is a catastrophic event 
even in the era of advanced reperfusion therapy. Herzog 
et al.20) reported that one- and two-year mortality rates 
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after acute myocardial infarction among patients on long 
term dialysis were 61% and 74%, respectively. An analysis 
of the USRDS Dialysis Morbidity and Mortality Study 
(DMMS) Wave 2 showed that the incidence of hospitali- 
zations for acute coronary syndrome was 29 per 1,000 
person years and the incidence of acute myocardial in-
farction (AMI) was 19 per 1,000 person years and one- 
and three-year mortality rates were 50% and 80%, respec- 
tively21). Although the absolute incidence and mortality 
rate of MI in advanced CKD patients is definitely in-
creased3), traditional risk factors for CVD are common 
in CKD. However, the degree to which CKD is associated 
with the risk of initial MI independently has not been 
well defined until now.
Pathogenesis
Traditional CVD risk factors are commonly present in 
CKD patients, but do not fully explain the high incidence 
of cardiovascular events or increased mortality rates in 
these patients22-24) and their association with cardiovas- 
cular outcomes could be attenuated or even reversed at 
the most advanced stages25). A wide variety of traditional 
and non-traditional CV risk factors are present in patients 
with CKD at all stages, but particularly in those receiving 
dialysis14). Traditional risk factors for CVD in patients 
with CKD are similar to those for the general population. 
They include older age, male sex, hypertension, diabetes 
mellitus, dyslipidemia, cigarette-smoking, physical inacti- 
vity, and a family history of premature CVD. A variety 
of non-traditional CV risk factors, such as hyperhomo- 
cysteinemia, increased oxidative stress and inflammation, 
endothelial cell dysfunction, activation of the renin-angio- 
tensin-aldosterone and the sympathetic nervous systems, 
vascular calcification due to abnormal calcium and phos-
phate metabolism, and anemia facilitate CVD risks in 
CKD. Many of the therapies that are highly effective in 
reducing CV risk in the general population are ineffective 
or marginally effective in patients with CKD, particularly 
those receiving dialysis26). Muntner et al.27) showed that 
some risk factors for coronary heart disease (CHD) among 
the general population still remain predictive among pa-
tients with CKD and control of these risk factors may 
have a substantial impact on their excess burden of CHD. 
Inflammation and oxidative stress have been associated 
with the pathogenesis of atheromatous plaque formation. 
Both non-traditional and traditional risk factors are advo-
cated with worse cardiovascular outcomes and the role 
of inflammation and its principal cause, oxidative stress, 
are investigated as potential targets of pharmacologic the- 
rapy28,29). The role of aldosterone in renal and cardiovas- 
cular injury, including inflammation, tissue remodeling 
and fibrosis, has been demonstrated and recently the role 
of mineralocorticoid excess in the development of cardio- 
vascular complications is increasingly recognized. Aldo- 
sterone can exert deleterious effects in the vascular system 
and kidney independently of angiotensin II30). Recently 
several studies have shown the impact of disordered 
mineral and bone metabolism on the pathogenesis of 
CAD in CKD patients31,32). Treatment with the active 
vitamin D analogue calcitriol appears to be associated 
with significantly greater survival in patients with CKD 
not yet receiving dialysis32). Abnormal vascular pathology in 
patients with CKD is attributable to two different mecha-
nisms, namely atherosclerosis and arteriosclerosis. Athe- 
rosclerosis is an intimal disease that is characterized by 
fibroatheromatous plaques and occlusive disease33). In 
CKD, there are distinct morphological differences com-
prised of increased plaque calcification and intimal and 
medial thickness34). These changes promote chronic my-
ocardial ischemia, particularly in the small distal coronary 
arteries and fibrosis, which may explain the high inci- 
dences of sudden cardiac death, heart failure and a lower 
incidence of acute plaque rupture in patients with CKD35). 
The other characteristic vascular pathology in CKD is the 
thickening and calcification of the medial arterial layer 
known as ‘arteriosclerosis’. Concomitant increased colla-
gen contents in the vessel wall, hyperplasia and hyper-
trophy of the vascular smooth muscle cells result in wall 
hypertrophy and stiffening of large conduit arteries33). 
These changes disturb arterial dampening function and 
result in increased systolic and pulse pressures. These alte- 
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rations influence an increased left ventricular afterload 
and myocardial oxygen demand and also influence altered 
coronary perfusion and sub-endocardial blood flow dis- 
tribution. There is little information regarding whether 
patients with CKD have a high incidence of vulnerable 
plaques in their coronary arteries. Recently, Nakano et 
al.36) reported that elderly patients with CKD have intimal 
neoangiogenesis and an increased risk of intraplaque 
hemorrhage in coronary arteries, possibly favored by local 
accumulation of oxidized low-density lipoprotein (LDL) 
and vascular endothelial growth factor (VEGF). Kato et 
al.37) also compare the coronary plaque characteristics of 
patients with and without CKD using optical coherence 
tomography (OCT). They identified 463 non-culprit cor-
onary plaques from 287 patients from the Massachusetts 
General Hospital OCT registry. Compared to non-CKD 
patients, the patients with CKD had a larger lipid index 
with a higher prevalence of calcium, cholesterol crystals 
and plaque disruption.
Diagnosis
Although coronary heart disease is extremely common 
in CKD patients, a routine screening test is not currently 
recommended in the absence of clinical symptoms and 
signs of cardiovascular disease. Early detection of coronary 
atheromatous plaque may possibly permit coronary vas-
cular interventions. However, the increased prevalence 
of CAD among CKD patients diminishes the negative pre-
dictive value of diagnostic studies in this population38). 
Also, major cardiovascular disease trials frequently exclude 
patients with renal disease and do not provide adequate 
information on the renal function of enrollees or the effect 
of interventions on patients with renal disease39). For these 
reasons, CKD patients are underrepresented in major car-
diac cohort studies evaluating the diagnostic sensitivities 
and specificities of non-invasive cardiac tests. In patients 
with CKD and symptomatic coronary heart disease, we 
usually do cardiac evaluations as in general populations. 
However, chest pain does not correlate well with CAD 
in CKD patients and severe CAD is common in asympto-
matic patients with CKD, because of autonomic dysfunc-
tion secondary to uremia and diabetes40). So, CV risk 
screening in CKD is unique in that there are no definite 
correlations between anatomic CAD and symptoms of 
CAD. Diagnosis of ACS may sometimes be problematic 
in CKD patients because the classic triad of ischemic symp- 
toms such as, chest pain, elevated cardiac biomarkers, and 
typical electrocardiographic changes is frequently absent. 
The clinical characteristics of dialysis patients hospitalized 
for AMI are strikingly different from those of nondialysis 
AMI patients. There are lower indexes of clinical suspicion 
for initial diagnosis of ACS, less chest pain, less ST eleva- 
tion, and twice frequent cardiac arrest in dialysis patients 
with AMI41). Sosnov et al.42) reported that patients with 
CKD are more likely to present with shortness of breath 
and less frequently present with symptoms relating to the 
arm, shoulder, neck, and chest pain. They concluded that 
patients with kidney disease experience AMI differently 
from patients without kidney disease. The etiology of these 
differences in AMI cannot be determined. However, kidney 
disease impacts on multiple organ systems, a large number 
of possible mechanisms exist by which kidney disease 
might affect the acute symptom profile. In patients with 
CKD and expecting kidney transplantation, conflicting 
data exists on the best method of cardiac screening. De 
Lima et al.43) evaluated prospectively the accuracy of 2 
noninvasive tests and risk stratification in detecting CAD 
(>or=70% obstruction) and assessing cardiac risk by 
using coronary angiography (CA). One hundred twenty- 
six renal transplant candidates underwent myocardial scin- 
tigraphy (SPECT), dobutamine stress echocardiography, 
and coronary angiography. They were followed for 6 to 
48 months. The prevalence of CAD was 42%. The sensiti- 
vities and negative predictive values for the 2 noninvasive 
tests and risk stratification were <75%. After 6 to 48 
months, there were 18 cardiac events, 9 fatal. Risk strat-
ification (p=0.007) and CA (p=0.0002) predicted the 
crude probability of surviving free of cardiac events. The 
probability of event-free survival at 6, 12, 24, 36, and 
48 months were 98%, 98%, 94%, 94%, and 94% in pa-
tients with <70% stenosis on CA and 97%, 87%, 61%, 
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56%, and 54% in patients with >or=70% stenosis. Multi- 
variate analysis showed that the sole predictor of cardiac 
events was critical coronary lesions (p=0.003). The au-
thors suggested that CA may still be necessary for detect-
ing CAD and may be the best screening method to detect 
CAD. Other studies have shown that simple clinical risk 
stratification as well as noninvasive testing is enough to 
reduce the morbidity and mortality of CV disease after 
kidney transplantation44). Any screening test is associated 
with false-positive and false-negative results that may lead 
to the possibility of additional and unnecessary diagnostic 
procedures. Last year, AHA/ACCF scientific statement re-
leased a new guideline. They recommend that noninvasive 
stress testing may be considered in kidney transplantation 
candidates with no active cardiac conditions on the basis 
of the presence of multiple CAD risk factors regardless 
of functional status. Relevant risk factors include diabetes 
mellitus, prior CVD, over 1 year on dialysis, left ventricle 
hypertrophy (LVH), age >60 year, smoking, hypertension, 
and dyslipidemia; the specific number of risk factors that 
should be used to prompt testing remains to be determined, 
but the committee considers >3 to be reasonable45).
Serum markers such as creatinine kinase (CK), CK-MB 
isoform, and cardiac troponins (cTns) may be elevated in 
the absence of true myocardial necrosis, possibly because 
of myocardial apoptosis or silent micro-infarction due to 
small vessel disease46). Whatever the mechanism involved, 
serial serum cardiac troponin level elevation is indicative 
of acute myocardial damage. This mandates careful atten-
tion to trends of serum cardiac troponin titers over time. 
In routine resting electrocardiography (EKG), LVH with 
a strain pattern which is frequently seen in patients with 
CKD may mask diagnostic ST depression in ACS. In case 
of exercise EKG, many CKD patients are not able to exer- 
cise fully to a level of diagnostic workload and the ST-seg-
ment response is not specific for myocardial ischemia40,47). 
The sensitivity and specificity of non-invasive cardiac tests 
in CKD patients is much lower than that in the general 
population. Radionuclide perfusion imaging is more sen-
sitive but less specific than stress echocardiography for 
diagnosis of significant CAD in patients on renal replace-
ment therapy40). Vandenberg et al.48) retrospectively com-
pared pharmacologic stress thallium scintigraphy with CA 
and demonstrated 62% sensitivity and 76% specificity 
for CA stenosis of >75%. Several factors attributed to 
the lower sensitivity in CKD population. CKD patients 
have higher levels of basal adenosine resulting in a high 
resting coronary flow. Pharmacologic myocardial perfu-
sion imaging uses dipyridamole (which works by increas-
ing endogenous adenosine levels) or adenosine as vasodi- 
lator to induce stress by challenging the flow reserve. 
Patel et al.49) studied 600 patients undergoing pre-KT 
evaluation and among these, 174 had SPECT imaging 
done. In these patients, adverse outcomes were predicted 
by an abnormal SPECT (the only multivariate predictor), 
whereas event free survival was 97% in patients with a 
normal SPECT over a 42 month follow-up period. Thus, 
a negative SPECT carries a very favorable prognostic value 
in the short and long term prediction of low cardiac events 
used as an endpoint. A positive SPECT also carries ad-
verse outcomes and warrants aggressive medical therapy 
and consideration of revascularization if ischemic burden 
is high. Echocardiography, in conjunction with stress by 
dobutamine or dipyridamole, is a standard method. How- 
ever, it should be cautioned that this method may be asso-
ciated with approximately 2%-4% risk of transient atrial 
fibrillation in dialysis patients, compared to only 0.5% 
in the general population. An advantage of echocardio- 
graphy is that prestress imaging can provide additional 
information on LV ejection fraction and dimensions, val- 
vular disease, pulmonary artery pressure, and volume status, 
as well as associated pericardial disease (e.g., pericardial 
effusion)50).
Treatment
Patients with CKD on dialysis experience extremely high 
mortality rates, especially from causes related to CVD5). 
The association of traditional risk factors with better sur-
vival in these patients, also termed ‘‘reverse epidemiology 
(RE)’’, have been described for over a decade and has 
led to a debate over the plausibility of these findings and 
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over the benefit of interventions targeting these tradi-
tional risk factors in patients on dialysis51). The altered 
relationship of traditional and nontraditional risk factors 
with cardiovascular outcomes in patients with CKD ensued 
and there were doubts about the relevance of existing 
standards of care to these patients39,52). The lack of defini-
tive randomized trials to treat CVD in patients with CKD 
leaves many questions. Currently, treatment decisions are 
often based on extrapolation from trials in other popu- 
lations and observational studies in CKD and dialysis 
patients. These unique features of coronary artery disease 
in CKD could reduce the absolute benefit of treatment 
with standard cardiovascular therapies. It is possible that 
patients with CKD have similar risk-benefit profiles from 
cardiovascular therapies compared with general popula- 
tion. However, there may be higher absolute benefit in 
patients with CKD, the absolute risks may also be higher 
leading to little or no risk-benefit. Evidence of the efficacy 
of traditional risk factor intervention such as, glycemic 
control, blood pressure (BP) control, dyslipidemia control, 
or lifestyle modification to reduce cardiovascular events 
in patients with advanced CKD remain limited. The role 
of glycemic control in diabetic ESRD is of growing impor- 
tance because of the magnitude of the population world-
wide and associated worse overall prognosis compared 
with the general dialysis population. Shurraw et al.53) re-
ported that in 1,484 incident North American hemodia- 
lysis patients during a follow-up of up to 8 years, increased 
serum glucose and hemoglobin A1c (HbA1c) levels were 
not independently and directly associated with mortality. 
Strict glycemic control may not benefit CKD 5D patients 
with or without diabetes mellitus. Hypertension as a risk 
factor for CVD in the general population is a well known 
fact. However, hypertension has not been consistently as-
sociated with adverse outcomes and in certain circum-
stances even seem to be protective. A ‘U-shaped’ curve 
has been observed between systolic blood pressure and car-
diovascular mortality among patients on dialysis, in con-
trast to a ‘J-shaped’ curve in the general population54,55). 
Randomized data on the efficacy of specific BP goals in 
CKD 5D patients are also lacking. The labile nature of 
BP and the absence of clear associations between hyper-
tension and adverse cardiovascular outcomes in CKD 5D 
preclude definitive recommendations about BP control56). 
For example, among incident hemodialysis patients, a 
low systolic blood pressure was associated with increased 
mortality during the first 2 years after starting dialysis, 
while a high systolic blood pressure was associated with 
increased mortality in patients who survived beyond 3 
years57). Dyslipidemia is frequently encountered in patients 
with CKD. KDOQI clinical practice guidelines recom-
mend a treatment goal of LDL-cholesterol level in adult 
patients with CKD to be less than 100 mg/dL58). However, 
data supporting the benefit of HMG CoA reductase in-
hibitors for dyslipidemia to reduce cardiovascular risk in 
patients with CKD are limited. Post hoc subgroup analy-
ses of large statin trials in the general population have 
suggested that the benefit of statin treatment in people 
with stage 3 CKD is similar to or greater than that of 
people with normal renal function. In the Pravastatin 
Pooling Project, among the 4,491 subjects with moderate 
CKD, pravastatin (40 mg daily) significantly reduced the 
incidence of the combined primary outcome of time to 
myocardial infarction, coronary death, or coronary re-
vascularization (HR=0.77, 95% CI=0.68-0.86) in pa-
tients with an eGFR of 30-59 ml/min per 1.73 m2, similar 
to the effect of pravastatin on the primary outcome in 
subjects with normal renal function (HR=0.78, 95% CI= 
0.65-0.94)59). However, in the PREVEND-IT (Prevention 
of Renal and Vascular End-stage Disease Intervention 
Trial) study, pravastatin was not associated with a reduc-
tion in risk of cardiovascular mortality and hospitaliza- 
tion for cardiovascular morbidity (RR=0.87, 95% CI= 
0.49-1.57, p=0.649)60). Two large clinical trials comparing 
statins with placebo in hemodialysis patients did not de- 
monstrate any clinical benefit61,62). In the randomized 4D 
study (Die Deutsche Diabetes Dialyze Studie), treatment 
with atorvastatin (20 mg daily) had no significant effect 
on the composite primary end point of cardiovascular death, 
nonfatal myocardial infarction and stroke (RR=0.92, 95% 
CI=0.77-1.10) compared with placebo, despite a 42% re-
duction in LDL-cholesterol levels in this high risk pop-
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ulation61). Investigators in the AURoRA(A Study to Evalu- 
ate the Use of Rosuvastatin in Subjects on Regular Hemo- 
dialysis: An Assessment of Survival and Cardiovascular 
Events) trial randomly assigned 2,776 patients on main-
tenance hemodialysis to rosuvastatin (10 mg daily) or 
placebo. Despite a 42.9% reduction in LDL-cholesterol 
levels, from a mean baseline value of 100±35 mg/dL, and 
an 11.5% reduction in median high sensitivity C reactive 
protein (CRP) levels, rosuvastatin had no effect on the 
combined primary end point of death from cardiovascular 
causes, nonfatal myocardial infarction and nonfatal stroke 
(HR=0.96, 95% CI=0.84-1.11) or on its individual com-
ponents62). Recently, the SHARP(Study of Heart and Renal 
Protection) trial results showed that reduction of LDL 
cholesterol with simvastatin 20 mg plus ezetimibe 10 mg 
daily safely reduced the incidence of major atherosclerotic 
events in a wide range of patients with advanced CKD. 
In the SHARP trial, the combination of simvastatin and 
ezetimibe in CKD patients (including CKD 5D) reduced 
major atherosclerotic events by 17%, but did not appear 
to reduce overall mortality. As no significant harm from 
statin use was also demonstrated, this reduction in non- 
fatal events provides a rationale for the use of statins in 
CKD patients despite the apparent lack of efficacy in re-
ducing the risk of death. After the SHARP trial results, 
statins may now be the best-studied evidence-based medi-
cal therapy in the context of advanced CKD63). Lifestyle 
modifications have not been widely studied in CKD pa-
tients; in a small trial, multifactorial intervention that in-
cluded smoking cessation was not associated with signi- 
ficant cardiovascular benefits64). Nevertheless, smoking 
cessation, exercise, dietary salt reduction, and weight loss 
are reasonable interventions at all CKD stages, and con-
trol of hypertension to usual goals or lower is indicated 
to slow CKD progression in patients with predialysis CKD. 
Data regarding efficacy of prophylactic aspirin in advanced 
CKD are sparse. Subgroup analyses of randomized trials 
have demonstrated convincing cardiovascular risk reduc-
tion from daily aspirin in individuals with estimated GFR 
<45 ml/min per 1.73 m2, including CKD 5D patients, de-
spite higher incidence of bleeding in CKD patients65,66).
There are no randomized trials of the benefits of re-
perfusion therapy in CKD. However, there is little reason 
to believe that renal function impairment diminishes the 
benefits of immediate reperfusion therapy in acute ST-ele- 
vation MI. Randomized controlled trials have demon-
strated better outcomes with primary percutaneous coro-
nary intervention (PCI) over fibrinolytic therapy in the 
treatment of ST segment elevation myocardial infarction 
(STEMI) patients with normal renal function67). Practice 
guidelines consider primary PCI as the preferred reperfu- 
sion strategy for patients presenting with STEMI. A recent 
retrospective analysis of STEMI patients from 2 large 
public hospitals in Singapore showed that patients with 
an admission GFR <60 mL/min per1.73 m2 who were 
treated with primary PCI, experienced a lower 30-day 
unadjusted mortality compared to patients treated with 
fibrinolysis. Adjusted mortality revealed a point estimate 
(adjusted OR, 0.7) favoring primary PCI over fibrinolysis; 
however, this did not achieve statistical significance 
(p=0.4). In contrast, among patients with an admission 
GFR ≥60 mL/min per 1.73 m2, primary PCI was asso-
ciated with a greater improvement in the point estimate 
(adjusted OR, 0.4), which achieved statistical significance 
(p=0.02). The authors suggest the need for randomized 
trials of primary PCI versus fibrinolytic therapy among 
patients with renal dysfunction who present with STEMI. 
However, when immediately available, primary PCI may 
be the treatment of choice irrespective of CKD status68). 
Among patients with impaired renal function presenting 
with STEMI, uncertainty remains as to which reperfusion 
strategy achieves superior outcomes. Although there are 
no randomized studies comparing primary PCI versus fi-
brinolytic therapy among STEMI patients with impaired 
renal function, observational studies have analyzed treat-
ment outcomes associated with either reperfusion strategy 
in this population69,70). In the 2002 Acute Coronary 
Syndrome Israeli Survey (ACSIS) studied to determine the 
effect of different myocardial reperfusion modalities on 
short- and long-term outcomes in 132 STEMI with renal 
failure patients. Thirty-day crude mortalities were 8.3% 
in the thrombolysis group, 40.0% in the primary PCI 
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group, and 29.7% in the no-reperfusion group (p<0.03). 
Crude and adjusted mortality odds ratios that were ob-
served at 7, 30, and 365 days, with the thrombolysis group 
as the reference, were 3.1 to 8.1 in the PCI group and 
1.5 to 4.6 in the no-reperfusion group. The authors sug-
gest that thrombolysis may represent the preferred mo-
dality of reperfusion therapy in patients with renal failure 
and ST-elevation acute myocardial infarction69). In the 
GRACE(Global Registry of Acute Coronary Events) study, 
the relative benefit of reperfusion was assessed in 12,532 
patients with renal dysfunction and ST-segment ele-
vation/left bundle branch block. As renal function de-
clined, hospital mortality and morbidity increased (both 
p<0.001) and reperfusion rates decreased. Fibrinolysis 
was not associated with reduced hospital or 6-month mor- 
tality in patients with renal dysfunction. Primary PCI was 
not associated with lower hospital mortality in patients 
with renal dysfunction but was associated with lower 
6-month mortality in those with moderate dysfunction. 
Both strategies of reperfusion were associated with higher 
mortality and outcomes remain poor with severe renal 
dysfunction, despite receipt of reperfusion therapy70). 
Among patients with non-ST elevation acute coronary 
syndrome (unstable angina and non-ST-elevation MI), the 
primary decision is between immediate angiography and 
a conservative approach. In the general population, an 
early invasive strategy reduces post-acute coronary syn-
drome morbidity and mortality. Analysis of 7 contempo- 
rary randomized trials in over 8,000 NSTE-ACS patients 
treated in the era of potent antiplatelet therapy and coro-
nary stents show that early invasive therapy decreases 
mortality by 25% at a mean of 2 years of follow-up, 
compared with a more conservative approach. Early in-
vasive therapy also decreases nonfatal myocardial infarc- 
tion by 17% and recurrent unstable angina requiring re-
hospitalization by 31%71). The survival of patients with 
CKD who undergo coronary revascularization is worse 
than for other patients with coronary artery disease. The 
association between renal dysfunction (RD) and worse 
outcomes after CABG surgery for patients not on dialysis 
has been linked closely. Both RD and ESRD are important 
risk factors for patients undergoing cardiopulmonary 
bypass. Despite this risk, increasing numbers of patients 
with RD and ESRD are being referred for coronary revas- 
cularization and CABG in particular. Operative mortality 
rose inversely with declining renal function, from 1.3% 
for those with normal renal function to 9.3% for patients 
with severe RD not on dialysis and 9.0% for those who 
were dialysis dependent. After adjustment for other co-
variates, preoperative GFR was one of the most powerful 
predictors of operative mortality and morbidities72). Con- 
versely, a recent retrospective analysis of all non-ST-ele-
vation MI patients in Sweden suggested that an early in-
vasive strategy was associated with greater 1-year survival 
in patients with non-ST-elevation MI and mild to mode- 
rate renal insufficiency, but the benefit declines with low-
er renal function, and harmful for CKD 5 patients73). 
There is a paucity of data regarding revascularization in 
CKD patients with stable angina. Surgical coronary revas- 
cularization is generally recommended for non-CKD pa-
tients with high-risk features such as left-main CAD, and 
PCI is typically recommended for symptomatic single- or 
two-vessel CAD or when a significant amount of myocar-
dium is at risk74,75). No randomized clinical trials directly 
compare coronary revascularization strategies in advanced 
CKD patients. For patients with CKD enrolled in the 
COURAGE (Clinical Outcomes Utilizing Revasculariza- 
tion and Aggressive Drug Evaluation) trial, optimal medi-
cal therapy was effective and associated with the same 
BP and lipid levels as in patients without CKD. A subgroup 
analysis of the COURAGE trial did not find a benefit 
from PCI compared with medical therapy in 320 patients 
with stage 3-4 CKD and predominantly anatomically 
low-risk, multivessel disease76). The ARTS (Arterial Revas- 
cularization Therapies Study) trial randomly assigned 
1,205 participants with and without CKD to CABG or 
PCI with multivessel stenting. Among them, 290 partici- 
pants (25%) had CKD at entry into ARTS. One hundred 
fifty-one received PCI, and 139 received CABG. No diffe- 
rence was observed in the primary endpoint with CABG 
or PCI among CKD participants (adjusted HR of CABG 
versus PCI=0.93; 95% CI=0.54-1.60; p=0.97). However, 
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CABG was associated with a reduced risk for repeat re-
vascularization (HR=0.28; 95% CI=0.14-0.54; p<0.01). 
Compared with participants with normal renal function, 
CKD was associated with a nearly 2-fold risk for the pri-
mary outcome (unadjusted HR=1.9; 95% CI=1.4-2.7; 
p<0.01). After multivariate adjustment, this association 
remained significant (HR=1.6; 95% CI=1.1-2.4). In this 
study, treatment with CABG or PCI with multivessel stent-
ing led to similar outcomes of death, MI, or stroke, but 
CABG was associated with decreased repeat revasculariza- 
tions. When compared with ARTS participants with nor-
mal renal function, those with CKD had a substantially 
elevated risk of adverse clinical outcomes after coronary 
revascularization77). Observational data consistently show 
increased risk of serious operative complications in CKD 
patients. Incidence of operative mortality after CABG rose 
inversely with declining renal function, from 1.3% for 
those with normal renal function to 9.3% for patients with 
severe renal dysfunction not on dialysis and 9.0% for 
those with dialysis72). Charytan and Kuntz78) reported that 
in-hospital death occurred in 11.1 % of dialysis patients 
compared to 3.4% of non-dialysis patients. Operative mor-
tality in dialysis patients still remains high despite recent 
advances in CABG surgery. However, among CKD patients 
undergoing coronary revascularization, death is more fre-
quent than ESRD. The incidence of ESRD was lower thro- 
ughout follow-up after PCI, but long-term risk of death 
was lower after CABG. Overall clinical outcome with 
CABG is better than with PCI in CKD patients79). Never- 
theless, PCI still may be an alternative therapeutic modality 
because of low perioperative mortality and morbidity com- 
pared with CABG surgery. In a study of CKD 5D patients 
undergoing first revascularization, in-hospital mortality 
was lower with PCI (4.1% versus 8.6%), but 2-year sur-
vival was better with CABG (56.4% versus 48.4%)80). 
Studies in the drug-eluting stent (DES) era provide conflic- 
ting evidence on their benefit in CKD patients. A retro-
spective study by Ishio et al.81) reported thatwhether DES 
was superior to bare metal stent (BMS) in 54 dialysis pa-
tients with 69 lesions. DES with sirolimus reduced in stent 
restenosis compared with BMS. However, no statistically 
significant difference was found for in-segment restenosis 
or target lesion revascularization. Few published data des- 
cribes the long-term survival of dialysis patients under-
going surgical versus percutaneous coronary revasculari-
zation in the era of DES. Shroff et al.82) recently conducted 
a retrospective study of 23,033 US dialysis patients who 
underwent coronary revascularizations (6,178 coronary 
artery bypass graftings, 5,011 BMS, 11,844 DES) from 
2004 to 2009. In-hospital mortality for coronary artery 
bypass grafting patients was 8.2%; all-cause survival at 
1, 2, and 5 years was 70%, 57%, and 28%, respectively. 
In-hospital mortality for DES patients was 2.7%; 1-, 2-, 
and 5-year survival was 71%, 53%, and 24%, respectively. 
Independent predictors of mortality were similar in both 
cohorts: age >65 years, white race, dialysis duration, peri- 
toneal dialysis, and congestive heart failure, but not dia-
betes mellitus. Survival was significantly higher for coro-
nary artery bypass grafting patients who received internal 
mammary grafts (IMG) (HR=0.83; p<0.0001). The pro- 
bability of repeat revascularization accounting for the 
competing risk of death was 18% with BMS, 19% with 
DES, and 6% with coronary artery bypass graftings at 1 
year. They concluded that among dialysis patients under-
going coronary revascularization, in-hospital mortality 
was higher after coronary artery bypass grafting, but long- 
term survival was superior with IMG. In-hospital mortality 
was lower for DES patients, but the probability of repeat 
revascularization was higher and comparable to that in 
patients receiving a BMS. The findings from this study 
support the recently popularized notion of adopting a 
heart team approach (i.e., deriving input from interven-
tional cardiologists and cardiovascular surgeons to deter- 
mine an individualized, optimal approach) for coronary 
revascularization in dialysis patients. DES may be a rea-
sonable consideration in dialysis patients in whom an IMG 
(typically used to bypass the left anterior descending cor-
onary artery vascular territory) is not an appropriate op-
tion in the revascularization strategy or whose overall life 
expectancy is judged to be limited. Revascularization de-
cisions for dialysis patients should be carefully performed 
and individualized.
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Conclusion
CKD has been shown to be an independent risk factor 
for cardiovascular events, and patients with pre-dialysis 
CKD appear to be more likely to die of heart disease 
than of kidney disease. CKD accelerates coronary artery 
atherosclerosis by several mechanisms, notably hyper-
tension and dyslipidemia, both of which are known risk 
factors for coronary artery disease. In addition, CKD alters 
calcium and phosphorus homeostasis, resulting in hyper-
calcemia and vascular calcification, including the coro-
nary arteries. Mortality of patients on long-term dialysis 
therapy is high, with age-adjusted mortality rates of about 
25% annually. Because the majority of deaths are caused 
by cardiovascular disease, routine cardiac catheterization 
of new dialysis patients was proposed as a means of impro- 
ving the identification and treatment of high-risk patients. 
However, clinicians may be uncomfortable exposing asymp- 
tomatic patients to invasive procedures such as cardiac 
catheterization, thus noninvasive cardiac risk stratification 
was investigated widely as a more palatable alternative to 
routine diagnostic catheterization. Whether invasive or non- 
invasive, the premise behind screening dialysis patients is 
that there is a high frequency of obstructive coronary artery 
disease (CAD) in this population, even in the absence of 
classic angina, and that intervention on asymptomatic obs- 
tructive coronary lesions could prevent heart attacks and 
cardiac death in long-term dialysis patients. The effective 
management of coronary artery disease is of paramount 
importance in uremic patients. The applicability of diag-
nostic, preventive, and treatment modalities developed in 
nonuremic populations to patients with kidney failure 
cannot necessarily be extrapolated from clinical studies 
in non-kidney failure populations. Vigorous attempts to 
treat lipid abnormalities in this population are appropriate, 
as is attention to other remediable coronary risk factors. 
Noninvasive diagnostic testing in uremic patients is less 
accurate than in nonuremic populations. Initial data sug-
gest that dobutamine echocardiography may be the pre-
ferred diagnostic method. Although some of the new anti-
platelet agents used in ACS require downward dose ad-
justment or are contraindicated, most anti-angina medi-
cations do not require dose adjustments for kidney dis- 
ease. Erythropoietin therapy is effective in reversing the 
cardiovascular perturbations that accompany the anemia 
of kidney failure, but an aggressive approach of normaliz-
ing the hematocrit cannot be recommended. Thrombolytic 
agents are underutilized in the management of MI. Coro- 
nary revascularization offers relative clinical advantages 
over medical therapy similar to non-kidney failure popula- 
tions. PCI with coronary stenting is the preferred revas- 
cularization approach, and conventional balloon PTCA 
is the least favorable approach. PCI with stenting is a 
less favorable alternative compared to CABG, however, 
it has with a faster recovery time, reduced invasiveness, 
and no overall mortality difference in nondiabetic and 
non-CKD patients compared with CABG. CABG is asso-
ciated with reduced repeat revascularizations, greater re-
lief of angina, and increased long term survival. However, 
CABG is associated with higher incidence of post-oper-
ative risks. The treatment chosen for each patient should 
be an individualized decision based upon numerous risk 
factors. CKD is associated with higher rates of CAD, with 
44% of all-cause mortality attributable to cardiac disease 
and about 20% from acute MI. Optimal treatment includ-
ing aggressive lifestyle modifications and concomitant 
medical therapy should be implemented in all patients 
to maximize benefits from either PCI or CABG. Future 
prospective randomized controlled trials with newer 
second or third generation DES and bioabsorbable DES 
are necessary to determine, if PCI may be noninferior 
to CABG in the future.
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